90y-daclizumab
mAbexperimentalADC
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 1996 (NCT00019227)
Timeline
1990s
- Jan 1, 1996
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Peripheral myelin protein 22Radiodepletion
PMP22 radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Also known as
- 90y-daclizumab
- y90 daclizumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01468311 | Phase 1/Phase 2 (Phase 2) | Oct 11, 2011 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
| NCT00019227 | Phase 1/Phase 2 (Phase 2) | Oct 1, 1996 | National Cancer Institute (NCI), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 2 | 1 | 1996 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 1996 |
2 organizations
Page 1 / 1